71.70
price up icon1.37%   0.97
 
loading
Novo Nordisk Adr stock is traded at $71.70, with a volume of 7.44M. It is up +1.37% in the last 24 hours and up +6.46% over the past month. With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
See More
Previous Close:
$70.73
Open:
$71.02
24h Volume:
7.44M
Relative Volume:
0.80
Market Cap:
$243.07B
Revenue:
$43.59B
Net Income/Loss:
$15.04B
P/E Ratio:
21.23
EPS:
3.3766
Net Cash Flow:
$10.74B
1W Performance:
+11.49%
1M Performance:
+6.46%
6M Performance:
-18.49%
1Y Performance:
-43.92%
1-Day Range:
Value
$70.58
$71.80
1-Week Range:
Value
$64.12
$71.80
52-Week Range:
Value
$57.00
$139.74

Novo Nordisk Adr Stock (NVO) Company Profile

Name
Name
Novo Nordisk Adr
Name
Phone
-
Name
Address
-
Name
Employee
77,406
Name
Twitter
@novonordisk
Name
Next Earnings Date
2024-12-06
Name
Latest SEC Filings
Name
NVO's Discussions on Twitter

Compare NVO with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Drug Manufacturers - General icon
NVO
Novo Nordisk Adr
71.70 314.28B 43.59B 15.04B 10.74B 3.3766
Drug Manufacturers - General icon
LLY
Lilly Eli Co
812.69 723.06B 49.00B 11.11B -1.27B 12.29
Drug Manufacturers - General icon
JNJ
Johnson Johnson
168.30 407.97B 90.63B 22.66B 16.40B 9.35
Drug Manufacturers - General icon
ABBV
Abbvie Inc
190.28 337.08B 57.37B 4.20B 15.39B 2.35
Drug Manufacturers - General icon
NVS
Novartis Ag Adr
117.70 227.39B 55.19B 13.65B 16.81B 6.86

Novo Nordisk Adr Stock (NVO) Upgrades & Downgrades

Date Action Analyst Rating Change
Apr-17-25 Downgrade BMO Capital Markets Outperform → Market Perform
Mar-13-25 Upgrade Kepler Hold → Buy
Mar-03-25 Downgrade Stifel Buy → Hold
Feb-12-25 Initiated Morgan Stanley Equal-Weight
Jan-06-25 Upgrade Bernstein Underperform → Mkt Perform
May-30-24 Initiated Goldman Buy
Apr-12-24 Initiated BMO Capital Markets Outperform
Jan-23-24 Initiated Morgan Stanley Overweight
Jan-16-24 Resumed UBS Neutral
Dec-01-23 Initiated Cantor Fitzgerald Overweight
Oct-02-23 Initiated Argus Buy
Jul-14-23 Initiated HSBC Securities Buy
Jul-15-22 Upgrade Morgan Stanley Equal-Weight → Overweight
Jun-28-22 Downgrade UBS Neutral → Sell
Jun-27-22 Upgrade Exane BNP Paribas Underperform → Neutral
Jun-07-22 Upgrade JP Morgan Neutral → Overweight
May-31-22 Upgrade Guggenheim Neutral → Buy
Apr-25-22 Upgrade Cowen Market Perform → Outperform
Apr-12-22 Upgrade Morgan Stanley Underweight → Equal-Weight
Mar-16-22 Upgrade Deutsche Bank Hold → Buy
Jan-25-22 Downgrade Liberum Hold → Sell
Dec-20-21 Downgrade JP Morgan Overweight → Neutral
Dec-17-21 Downgrade Deutsche Bank Buy → Hold
Jan-20-21 Downgrade Credit Suisse Outperform → Neutral
Jan-15-21 Initiated Deutsche Bank Buy
Sep-29-20 Initiated Berenberg Hold
Jul-06-20 Downgrade BofA Securities Buy → Neutral
May-11-20 Downgrade UBS Buy → Neutral
May-04-20 Initiated Cowen Market Perform
Mar-16-20 Upgrade BofA/Merrill Neutral → Buy
Jan-03-20 Downgrade Guggenheim Buy → Neutral
Nov-18-19 Upgrade Barclays Equal Weight → Overweight
Sep-17-19 Upgrade Citigroup Neutral → Buy
Aug-30-19 Downgrade Jefferies Hold → Underperform
Jun-20-19 Downgrade Deutsche Bank Buy → Hold
Jun-11-19 Upgrade Barclays Underweight → Equal Weight
Apr-29-19 Upgrade Credit Suisse Neutral → Outperform
Jan-29-19 Initiated Exane BNP Paribas Outperform
Dec-11-18 Resumed Jefferies Hold
Oct-09-18 Initiated Guggenheim Buy
Dec-29-17 Upgrade JP Morgan Underweight → Neutral
Dec-06-17 Upgrade BofA/Merrill Neutral → Buy
Dec-01-17 Upgrade Morgan Stanley Equal-Weight → Overweight
Sep-25-17 Downgrade Exane BNP Paribas Outperform → Neutral
Sep-06-17 Upgrade BofA/Merrill Underperform → Neutral
View All

Novo Nordisk Adr Stock (NVO) Latest News

pulisher
07:08 AM

HIMS STOCK UPDATE: Hims & Hers Health, Inc. (NYSE:HIMS) is being Sued for Securities Fraud – Contact BFA Law by August 25 Class Action Deadline - GlobeNewswire Inc.

07:08 AM
pulisher
Jul 25, 2025

Hims & Hers Health, Inc. Sued for Securities Law Violations - GlobeNewswire Inc.

Jul 25, 2025
pulisher
Jul 23, 2025

HIMS & HERS HEALTH SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuits Against Hims & Hers Health, Inc. - GlobeNewswire Inc.

Jul 23, 2025
pulisher
Jul 23, 2025

European ADRs Inch Higher As Drugmakers Shine - Finimize

Jul 23, 2025
pulisher
Jul 16, 2025

Novo Nordisk’s GLP-1 Reign Faces New Pressures In 2025 - Finimize

Jul 16, 2025
pulisher
Jul 15, 2025

HIMS & HERS HEALTH SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuits Against Hims & Hers Health, Inc. - GlobeNewswire Inc.

Jul 15, 2025
pulisher
Jul 15, 2025

NVO’s 2025 Market Dance: Down -51.70% – Time to Invest? - investchronicle.com

Jul 15, 2025
pulisher
Jun 24, 2025

Novo Nordisk's Cardiometabolic Foundation Supports Wide Moat - Morningstar

Jun 24, 2025
pulisher
Jun 22, 2025

Novo Nordisk: Navigating Challenges to Dominate Diabetes and Obesity Therapies - AInvest

Jun 22, 2025
pulisher
Jun 19, 2025

The Skinny On Novo Nordisk: This Slimmed-Down Stock May Be Worth A... Shot - Finimize

Jun 19, 2025
pulisher
Jun 17, 2025

NVO’s Stock Woes: Down -31.04% in 6 Months, Down -31.04% in Just 5 Days - investchronicle.com

Jun 17, 2025
pulisher
Jun 16, 2025

European Stocks Shine As ADRs Climb Higher - Finimize

Jun 16, 2025
pulisher
Jun 13, 2025

After ousting CEO, Novo Nordisk reclaims crown as largest European company - MSN

Jun 13, 2025
pulisher
Jun 10, 2025

Why Novo Nordisk Stock Just Popped - Barchart.com

Jun 10, 2025
pulisher
May 31, 2025

European ADRs Show Strength With Genfit And Novo Nordisk Leading Gains - Finimize

May 31, 2025
pulisher
May 30, 2025

European ADRs Show Resilience In US Market - Finimize

May 30, 2025
pulisher
May 19, 2025

Novo Nordisk Faces Obesity Competition, but Innovation Still Warrants a Wide Moat - Morningstar

May 19, 2025
pulisher
May 19, 2025

Bio/Pharmaceutical Outsourcing Report, March 2025 Edition - GlobeNewswire Inc.

May 19, 2025
pulisher
May 16, 2025

European ADRs Dip As Pharma And Tech Stocks See Mixed Results - Finimize

May 16, 2025
pulisher
May 13, 2025

What Did We Find About Insider Trading At Novo Nordisk ADR (NYSE: NVO)? - Stocksregister

May 13, 2025
pulisher
May 10, 2025

European Stocks Show Mixed Results With Novo Nordisk Leading Gains - Finimize

May 10, 2025
pulisher
May 09, 2025

Novo Nordisk Q1 Earnings Match Estimates, Revenues Rise Y/Y, Stock Up - MSN

May 09, 2025

Novo Nordisk Adr Stock (NVO) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
drug_manufacturers_general NVS
$117.70
price up icon 0.20%
drug_manufacturers_general MRK
$84.71
price up icon 0.71%
$306.58
price down icon 0.64%
$190.28
price down icon 0.29%
$116.20
price up icon 2.65%
Cap:     |  Volume (24h):